|
|
Blood, 1 December 2006, Vol. 108, No. 12, pp. 3662-3667.
Prepublished online as a Blood First Edition Paper on August 15, 2006; DOI 10.1182/blood-2006-06-030577.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100
Rebecca M. Shepherd,
Benjamin J. Capoccia,
Steven M. Devine,
John DiPersio,
Kathryn M. Trinkaus,
David Ingram, and
Daniel C. Link
From the Division of Rheumatology, Division of Oncology, and Division of Biostatistics, Washington University School of Medicine, St Louis, MO; Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis; and The Ohio State University School of Medicine and Public Health, Columbus.
Circulating endothelial progenitor cells (EPCs) are thought to contribute to angiogenesis following vascular injury, stimulating interest in their ability to mediate therapeutic angiogenesis. However, the number of EPCs in the blood is low, limiting endogenous repair, and a method to rapidly mobilize EPCs has not been reported. In this study, healthy donors were mobilized sequentially with the CXCR4 antagonist, AMD3100, and G-CSF. The number of EPCs and circulating angiogenic cells (CACs) in the blood and pheresis product was determined and the angiogenic capacity of each cell population assessed. Compared with baseline, treatment with AMD3100 or G-CSF increased the number of blood CACs 10.0-fold ± 4.4-fold and 8.8-fold ± 3.7-fold, respectively. The number of EPCs in the blood increased 10.2-fold ± 3.3-fold and 21.8-fold ± 5.4-fold, respectively. On a percell basis, CACs harvested from G-CSF–mobilized blood displayed increased in vivo angiogenic potential compared with AMD3100-mobilized CACs. Mobilized EPCs displayed a greater proliferative capacity than EPCs isolated from baseline blood. Both CACs and EPCs were efficiently harvested by leukapheresis. Cryopreserved CACs but not EPCs retained functional activity after thawing. These data show that AMD3100 is a potent and rapid mobilizer of angiogenic cells and demonstrate the feasibility of obtaining and storing large numbers of angiogenic cells by leukapheresis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
"Quick" fix to add to the mix?
- Mervin C. Yoder
Blood 2006 108: 3625-3626.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
Y. J. Cao, C. W. Flexner, S. Dunaway, J.-G. Park, K. Klingman, I. Wiggins, J. Conley, C. Radebaugh, A. D. Kashuba, R. MacFarland, et al.
Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers
Antimicrob. Agents Chemother.,
May 1, 2008;
52(5):
1630 - 1634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asosingh, M. A. Aldred, A. Vasanji, J. Drazba, J. Sharp, C. Farver, S. A.A. Comhair, W. Xu, L. Licina, L. Huang, et al.
Circulating Angiogenic Precursors in Idiopathic Pulmonary Arterial Hypertension
Am. J. Pathol.,
March 1, 2008;
172(3):
615 - 627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nogueras, A. Merino, R. Ojeda, J. Carracedo, M. Rodriguez, A. Martin-Malo, R. Ramirez, and P. Aljama
Coupling of endothelial injury and repair: an analysis using an in vivo experimental model
Am J Physiol Heart Circ Physiol,
February 1, 2008;
294(2):
H708 - H713.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zernecke, I. Bot, Y. Djalali-Talab, E. Shagdarsuren, K. Bidzhekov, S. Meiler, R. Krohn, A. Schober, M. Sperandio, O. Soehnlein, et al.
Protective Role of CXC Receptor 4/CXC Ligand 12 Unveils the Importance of Neutrophils in Atherosclerosis
Circ. Res.,
February 1, 2008;
102(2):
209 - 217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Xu, J. Sui, H. Tao, Q. Zhu, and W. A. Marasco
Human Anti-CXCR4 Antibodies Undergo VH Replacement, Exhibit Functional V-Region Sulfation, and Define CXCR4 Antigenic Heterogeneity
J. Immunol.,
August 15, 2007;
179(4):
2408 - 2418.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
